11th Conference on Retroviruses and Opportunistic Infections

Español (soon!) - July 4, 2008

CMEonHIV.com is dedicated to providing online CME presentations (slides with voiceover) on HIV/AIDS for healthcare professionals given by local and international experts to keep you up-to-date on the ongoing developments in the field.

Conference

"11th Conference on Retroviruses and Opportunistic Infections"
Dr. Sharon Walmsley (biography)
English - 2004-03-17 - 83 minutes

(18 slides)

(25 slides)

Summary :
In this presentation Dr Walmsley does a review of the findings from several studies presented at the 11th CROI meeting, relating to the topics of antiretroviral therapy and resistance, management of HIV/HCV coinfection and management of antiretroviral toxicity.

Topics discussed will include the performance of all-NRTI regimens compared to standard HAART, effects of the long half-life of NNRTIs in prolonging the therapeutic effect after stopping the drug, performance of peg-IFN/RBV in the treatment of HIV/HCV coinfected patients, and new information on antiretroviral toxicities such as hepatic steatosis in HCV coinfected patients, lipoatrophy, renal insufficiency and anal dysplasia.

Copyright © 2004 E-MedHosting.com Inc

Learning objectives :
The participant will review new data presented at the 11th CROI meeting relating to the following topics:

-Antiretroviral Therapy
-Antiretroviral Resistance
-Management of HIV/HCV Coinfection
-Antiretroviral Toxicity and its Management

Bibliographic references :
A Carr et al. Rosiglitazone for the Treatment of HIV Lipoatrophy: A Double-blind, Placebo-controlled, 48-week Trial 11thCROI#79

R Chung et al. A Randomized, Controlled Trial of PEG-Interferon-alfa-2a plus Ribavirin vs Interferon-alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV-co-infected Persons: Follow-up Results of ACTG A5071 11th CROI#110

E DeJesus et al. Efficacy and Safety of Atazanavir with Ritonavir or Saquinavir vs Lopinavir/Ritonavir in Patients Who Have Experienced Virologic Failure on Multiple HAART Regimens: 48-Week Results from BMS A1424-045 11th CROI #547

U Dragsted et al. Final Week 48 Analysis of a Phase 4, Randomised, Open-label, Multi-center Trial to Evaluate Safety and Efficacy of Continued Lamivudine Twice Daily Versus Discontinuation of Lamivudine in HIV-1-infected Adults with Virological Failure on Ongoing Combination Treatments Containing Lamivudine: The COLATE Trial 11th CROI #549

M Dube et al. Prospective Study of Glucose and Lipid Metabolism in Antiretroviral-Naive Subjects Randomized to Receive Nelfinavir, Efavirenz, or Both Combined with Zidovudine+Lamivudine (ZDV+3TC) or Didanosine+Stavudine: A5005s, a Substudy of ACTG 384 11thCROI#74

R Elion et al. COL40263: Resistance and Efficacy of Once-daily Trizivir and Tenofovir DF in Antiretroviral Naïve Subjects 11th CROI #53

J Gathe et al. Once-daily vs Twice-daily Lopinavir/ritonavir in Antiretroviral-naive Patients: 48-Week Results 11th CROI #570

D Haas et al. A Common CYP2B6 Variant Is Associated with Efavirenz Pharmacokinetics and Central Nervous System Side Effects: AACTG Study NWCS214 11th CROI #133

S Hammer et al. Randomized, Placebo-Controlled Trial of Abacavir Intensification in HIV-1-infected Adults with Plasma HIV RNA <500 Copies/mL 11th CROI #56

J Hitti et al. Sex and Weight as Covariates in the Pharmacokinetics of Efavirenz, Indinavir, and Nelfinavir 11th CROI #604

J Jemsek, P Hutcherson, and E Harper.Poor Virologic Responses and Early Emergence of Resistance in Treatment Naive, HIV-infected Patients Receiving a Once Daily Triple Nucleoside Regimen of Didanosine, Lamivudine, and Tenofovir DF 11th CROI #51

G Jourdain et al. Exposure to Intrapartum Single-dose Nevirapine and Subsequent Maternal 6-Month Response to NNRTI-based Regimens 11th CROI#41LB

D Kaufmann et al. Limited Durability of Immune Control following Treated Acute HIV Infection 11th CROI #24

M Kearney et al. Single-genome Sequencing Is More Sensitive than Standard Genotype Analysing ets for Detection of HIV-1 Drug-resistance Mutations 11th CROI#695

R Landman et al. Low Genetic Barrier to Resistance Is a Possible Cause of Early Virologic Failures in Once-Daily Regimen of Abacavir, Lamivudine, and Tenofovir: The Tonus Study 11th CROI #52

S Little et al. Persistence of Transmitted Drug-resistant Virus among Subjects with Primary HIV Infection Deferring Antiretroviral Therapy 11th CROI#36LB

B Masquelier et al. Changes in Prevalence and Characteristics of Transmitted Resistance over Time among European Seroconverter Cohorts 11th CROI #683

J Mellors et al. Low-frequency NNRTI-resistant Variants Contribute to Failure of Efavirenz-containing Regimens 11th CROI#39

C Perronne et al. Final Results of ANRS HC02-RIBAVIC: A Randomized Controlled Trial of Pegylated-Interferon-alfa-2b plus Ribavirin vs Interferon-alfa-2b plus Ribavirin for the Initial Treatment of Chronic Hepatitis C in HIV Co-infected Patients 11th CROI # 117LB

D Pillay et al. The Effect of Transmitted Drug Resistance on Virological Response to HAART Regimens Adjusted for Genotypic Resistance at Baseline 11th CROI#685

H Ribaudo et al. Relationships between Efavirenz Pharmacokinetics, Side Effects, Drug Discontinuation, Virologic Response, and Race: Results from ACTG A5095/A5097s 11th CROI #132

M Sulkowski et al. Population Prevalence of Hepatic Steatosis among Antiretroviral-experienced HCV/HIV Co-infected Adults with and without Stavudine Exposure 11th CROI#72

S Taylor et al. Stop Study: After Discontinuation of Efavirenz, Plasma Concentrations May Persist for 2 Weeks or Longer 11th CROI #131

F Torriani et al. Final Results of APRICOT: A Randomized, Partially Blinded, International Trial Evaluating Peginterferon-alfa-2a + Ribavirin vs Interferon-alfa-2a + Ribavirin in the Treatment of HCV in HIV/HCV Co-infection 11th CROI #112

Login

	Please log in and get access to thousands of resources about HIV disease and its treatment.
	Already a member?
	Username :
	Password :

	Lost your password?

Search our database

Find the information that you are looking for in over +3000 resources.

USER ACKNOWLEDGES AND AGREES THAT ALL DECISIONS MADE WITH THE ASSISTANCE OR USE OF THE SOFTWARE AND/OR THE WEBSITE AND/OR
BASED ON CONTENT FOUND HEREIN WILL BE EXCLUSIVELY THE RESPONSIBILITY OF THE USER.